FDA approves record number of personalized medicines in 2017

Personalized medicines now account for more than one in four new drug approvals
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
WASHINGTON. D.C.—The Personalized Medicine Coalition (PMC) in late January released a report documenting the record number of new personalized medicines the U.S. Food and Drug Administration (FDA) approved last year, making 2017 the fourth consecutive year that personalized medicines accounted for more than 20 percent of all new drug approvals.
 
The annual analysis, titled “Personalized Medicine at FDA: 2017 Progress Report,” shows that FDA approved a record number of 19 personalized medicines—16 new molecular entities and three gene therapies—in 2017.
 
Specifically, the report lists a total of six regulatory precedents FDA set last year, as follows: (1) A record number of 16 personalized medicines approved as new molecular entities; (2) the approval of first three gene therapies; (3) the first approval of a tissue-agnostic indication for cancer therapy; (4) the first authorization for marketing of health-related genetic tests directly to consumers; (5) the first approval of a personalized medicine biosimilar; and (6) the first FDA/CMS joint approval and coverage decision for a next-generation sequencing test.
 
PMC President Dr. Edward Abrahams said the precedents demonstrate how personalized medicine has reshaped drug development in the decade since 2007, when targeted therapies accounted for less than 10 percent of new drug approvals.
 
As the PMC points out, an influential article published in 2007 in the Harvard Business Review titled “Realizing the Promise of Personalized Medicine,” for example, suggested that FDA was not yet committed to the paradigm. The pharmaceutical industry, the article noted, was at that time hesitant to develop medicines for smaller patient populations, preferring instead to develop “blockbuster” medications that could earn approval for one-size-fits-all applications.
 
This obviously is no longer true, the PMC remarks, though there remain many obstacles—notably regarding regulation, reimbursement, access and clinical adoption—that complicate the commercialization of personalized medicine products.
 
“Despite myriad challenges, the diagnostic and pharmaceutical industries are deeply invested in making healthcare more effective and efficient by developing products that guide treatments to only those patients who will benefit from them,” Abrahams explained. “As this report shows, FDA is increasingly committed to supporting that effort.”

Related Topics

Published In

Volume 14 - Issue 3 | March 2018

March 2018

March 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue